Zabrina Watkins named diversity, equity, and inclusion director for Prime Therapeutics

March 28, 2022

Prime Therapeutics (Prime) recently named Zabrina Watkins its new diversity, equity and inclusion (DEI) director.

“At Prime, we’re committed to fostering a culture of inclusion, where everyone feels they can belong and thrive,” said Watkins. “This year we published our first DEI transparency report, highlighting steps we’ve taken toward enhancing workplace inclusion and pledging to continue this important journey,” Watkins added.

Effective March 1, 2022, Watkins assumed the role to build on current and future DEI initiatives for Prime. At Prime, Watkins previously served as co-chair for Prime’s Diversity & Inclusion (D&I) Council and now serves on its Alumni Board. Watkins also currently serves as a lead for Prime’s Black Professionals + Allies employee resource group.

“I am humbled to take on the role of DEI director,” Watkins said. “And I look forward to continuing to build upon the solid foundation and framework for strategies, programs and initiatives that reinforce Prime’s commitment to a more equitable and inclusive organization.”

Prime’s commitment to diversity, equity and inclusion is rooted in its collective values as a company and inseparable from Prime’s purpose and dedication to serving others. Going forward, Prime will further its mission to champion DEI awareness, outreach and events, engaging its employees on a journey toward making workplace inclusion a part of its DNA.

Related news

Stories

May 13, 2022

Prime expert showcases medical specialty drug management solutions

Prime Therapeutics’ (Prime) Chris Ford, assistant vice president, strategy and innovation, was a…

Stories

March 31, 2022

Prime pharmacist recognized for high-quality clinical research

The American Pharmacists Association (APhA) awarded Ben Urick, PharmD, PhD, principal health outcomes…